ASO Author Reflections: Is ctDNA Detection an Accurate Measure of the Risk of Recurrence in Patients Undergoing Neoadjuvant Treatment?

Mikail Gögenur¹, Claus Lindbjerg Andersen^{2

3

4}, Ismail Gögenur^{5

2}

Affiliations

¹ Center for Surgical Science, Zealand University Hospital Køge, Lykkebækvej 1, 4600, Køge, Denmark. mgog@regsj.dk.
² Danish Colorectal Cancer Group, Copenhagen, Denmark.
³ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Center for Surgical Science, Zealand University Hospital Køge, Lykkebækvej 1, 4600, Køge, Denmark.

Comment

Mikail Gögenur et al. Ann Surg Oncol. 2022 Dec.

. 2022 Dec;29(13):8675.

doi: 10.1245/s10434-022-12378-3. Epub 2022 Aug 5.

Mikail Gögenur¹, Claus Lindbjerg Andersen^{2

3

4}, Ismail Gögenur^{5

2}

¹ Center for Surgical Science, Zealand University Hospital Køge, Lykkebækvej 1, 4600, Køge, Denmark. mgog@regsj.dk.
² Danish Colorectal Cancer Group, Copenhagen, Denmark.
³ Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
⁴ Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
⁵ Center for Surgical Science, Zealand University Hospital Køge, Lykkebækvej 1, 4600, Køge, Denmark.

No abstract available

Comment on

ctDNA for Risk of Recurrence Assessment in Patients Treated with Neoadjuvant Treatment: A Systematic Review and Meta-analysis.
Gögenur M, Hadi NA, Qvortrup C, Andersen CL, Gögenur I. Gögenur M, et al. Ann Surg Oncol. 2022 Dec;29(13):8666-8674. doi: 10.1245/s10434-022-12366-7. Epub 2022 Aug 6. Ann Surg Oncol. 2022. PMID: 35933546

1. Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–46. https://doi.org/10.1056/nejmoa010580 . - DOI - PubMed
1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by Ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–31. https://doi.org/10.1001/jamaoncol.2019.0528 . - DOI - PubMed - PMC
1. Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res. 2022;28(3):507–17. https://doi.org/10.1158/1078-0432.CCR-21-2404 . - DOI - PubMed
1. Gögenur M, Hadi A-HH, Qvortrup C, Andersen CL, Gögenur I. ctDNA for risk of recurrence assessment in patients treated with neoadjuvant treatment: a systematic review and meta-analysis. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12366-7 . - DOI - PubMed